TY - JOUR
T1 - Novel treatment of chronic severe hand dermatitis with bexarotene gel
AU - Hanifin, J. M.
AU - Stevens, V.
AU - Sheth, P.
AU - Breneman, D.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2004/3
Y1 - 2004/3
N2 - Background: Hand dermatitis is an eczematous inflammation of the hands that is related to occupation or to routine activities. It often becomes chronic, and in some patients may become severe and disabling. Topical corticosteroids are effective treatment, particularly for milder forms, but they often lose effectiveness with time and can produce skin atrophy. Objectives: To evaluate bexarotene gel topical therapy for safety, tolerability and efficacy in patients with chronic hand dermatitis. Methods: A phase I-II open-label randomized clinical study of bexarotene gel, alone and in combination with a low- and a mid-potency steroid, was conducted in 55 patients with chronic severe hand dermatitis at two academic clinics. Results: Patients using bexarotene gel monotherapy reached a 79% response rate for ≥50% clinical improvement and a 39% response rate for ≥90% clearance of hands. Adverse events possibly related to treatment in all patients were stinging or burning (15%), flare of dermatitis (16%) and irritation (29%). Thirteen patients (24%) withdrew early, including two for related adverse events and five for inadequate response. Conclusions: Bexarotene gel appears to be safe, tolerated by most patients, with useful therapeutic activity in chronic severe hand dermatitis.
AB - Background: Hand dermatitis is an eczematous inflammation of the hands that is related to occupation or to routine activities. It often becomes chronic, and in some patients may become severe and disabling. Topical corticosteroids are effective treatment, particularly for milder forms, but they often lose effectiveness with time and can produce skin atrophy. Objectives: To evaluate bexarotene gel topical therapy for safety, tolerability and efficacy in patients with chronic hand dermatitis. Methods: A phase I-II open-label randomized clinical study of bexarotene gel, alone and in combination with a low- and a mid-potency steroid, was conducted in 55 patients with chronic severe hand dermatitis at two academic clinics. Results: Patients using bexarotene gel monotherapy reached a 79% response rate for ≥50% clinical improvement and a 39% response rate for ≥90% clearance of hands. Adverse events possibly related to treatment in all patients were stinging or burning (15%), flare of dermatitis (16%) and irritation (29%). Thirteen patients (24%) withdrew early, including two for related adverse events and five for inadequate response. Conclusions: Bexarotene gel appears to be safe, tolerated by most patients, with useful therapeutic activity in chronic severe hand dermatitis.
KW - Bexarotene
KW - Hand eczema
KW - Irritant contact dermatitis
KW - Rexinoid
UR - http://www.scopus.com/inward/record.url?scp=1842506669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1842506669&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2133.2003.05729.x
DO - 10.1046/j.1365-2133.2003.05729.x
M3 - Article
C2 - 15030340
AN - SCOPUS:1842506669
SN - 0007-0963
VL - 150
SP - 545
EP - 553
JO - British Journal of Dermatology
JF - British Journal of Dermatology
IS - 3
ER -